Bortiva 2mg contains Bortezomib, a first-in-class proteasome inhibitor that has significantly advanced the treatment of multiple myeloma and certain lymphomas.
It is administered as a subcutaneous injection or intravenous infusion, typically in cycles, and has become a cornerstone therapy by helping control disease progression and prolonging survival.

Mechanism of Action

Bortezomib targets the 26S proteasome, a cellular complex responsible for breaking down unwanted or damaged proteins.

• In multiple myeloma and some lymphoma cells, rapid protein turnover is essential for their uncontrolled growth.

• By inhibiting the proteasome, bortezomib causes a buildup of these proteins, disrupting multiple signaling pathways.

• This stress leads to cell cycle arrest and programmed cell death (apoptosis) of cancer cells.

  Uses / Indications

  Bortiva 2mg is used in the treatment of:

  • Multiple myeloma (MM):

    • As first-line therapy in newly diagnosed patients (often combined with other drugs like dexamethasone, lenalidomide, or cyclophosphamide).

    • In relapsed or refractory disease to regain control of progression.

  • Mantle cell lymphoma (MCL):

    • Particularly in patients who have received at least one prior therapy.

  It is typically given once or twice weekly in 3- to 4-week cycles, with rest periods to allow the body to recover.

  Adverse Effects

  Because it interferes with core cellular functions, bortezomib can affect both cancerous and healthy fast-dividing cells.

  Common side effects include:

  • Peripheral neuropathy (numbness, tingling, burning in hands or feet) — one of the most important side effects, which may improve after dose adjustments or treatment completion.

  • Fatigue, mild nausea, diarrhoea or constipation.

  • Low blood counts (white cells, red cells, platelets), increasing risks of infection, anaemia, and bleeding.

  • Mild rash or injection site reactions.